Abstracts tagged "rheumatoid arthritis"

Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 2083 • 2012 ACR/ARHP Annual Meeting
New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9
Annelie Hellvard¹, Lutz Zeitlmann², Ulrich Heiser³, André Niestroj³, Hans-Ulrich Demuth³, Jan Potempa⁴ and Piotr Mydel¹, ¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ²Ingenium Pharmaceuticals GmbH, Martinsried, Germany, ³Probiodrug AG, Halle/Saale, Germany, ⁴Microbiology Department, Jagiellonian University, Krakow, Poland
Background/Purpose: Cyclin dependent kinase-9 (cdk-9) is transcription regulator of the carboxyterminal domain of RNA polymerase II. The usage of pan-cdk inhibitors such as flavopiridol has…
Abstract Number: 1636 • 2012 ACR/ARHP Annual Meeting
Commensal Gut-Derived Bacteria As Therapy for Systemic Autoimmune Disease
David Luckey¹, Eric Marietta¹, Harvinder S. Luthra², Robin Patel³, Joseph A. Murray⁴, Ashutosh Mangalam¹ and Veena Taneja¹, ¹Immunology, Mayo Clinic, Rochester, MN, ²Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ³Medicine, Mayo Clinic, Rochester, MN, ⁴Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that leads to destruction of joints. Although etiology of RA is unknown, both genetic and environmental factors…
Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Karine Briot¹, Thierry Schaeverbeke², Fabien Etchepare³, Philippe Gaudin⁴, Aleth Perdriger⁵, Muriel Vray⁶, Stephanie Rouanet⁷, Ghislaine Steinberg⁸ and Christian Roux¹, ¹Cochin hospital, Paris Descartes University, Paris, France, ²Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ³G.H. Pitié-Salpêtrière, Paris, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Institut Pasteur, Paris, France, ⁷Medical Department, Roche, Boulogne-Billancourt, France, ⁸Medical Department, Roche, Neuilly sur Seine, France
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…
Abstract Number: 346 • 2012 ACR/ARHP Annual Meeting
Sclerostin Protects Against Inflammatory Bone Loss by Regulating Tnfalpha Mediated p38-Mapkinase Activation
Corinna Wehmeyer¹, Christina Wunrau¹, Athanasios Stratis¹, Ina Kramer², Michaela Kneissel², Thomas Pap³ and Berno Dankbar¹, ¹Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Muenster, Muenster, Germany, ²Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland, ³Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany
Background/Purpose: Progressive loss of joint structure is a hallmark of rheumatoid arthritis (RA). TNFα has been shown to promote the destruction of bone by increasing…
Abstract Number: 2073 • 2012 ACR/ARHP Annual Meeting
Green Tea Epigallocatechin-3-Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf2 Antioxidant Pathway
Soyoun Min¹, Mei Yan¹, Kamala Vanarsa², Anna Bashmakov¹ and Chandra Mohan¹, ¹Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: To examine the immunomodulatory effects and mechanisms of Green Tea (−)-epigallocatechin-3-gallate (EGCG) on experimental arthritis in mice, we investigated whether EGCG can afford therapeutic…
Abstract Number: 1561 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Implementation of Intensive Treatment Strategies for Early Rheumatoid Arthritis
Sabrina Meyfroidt¹, Diederik De Cock¹, Kristien Van der Elst², Laura van Hulst³, Marlies Hulscher³, Johan Joly⁴, Rene Westhovens⁵ and Patrick Verschueren⁵, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²Department of Development and Regeneration, Neuro-musculo-skeletal Research Unit, University Hospitals KULeuven, Leuven, Belgium, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁵Rheumatology, University Hospitals KULeuven, Leuven, Belgium
Background/Purpose: Despite the availability and demonstrated effectiveness of intensive treatment strategies for early rheumatoid arthritis (RA), a discrepancy seems to exist between theoretical acceptance and…
Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Clifton O. Bingham III¹, Warren C. Rizzo², Micki Klearman³, Azra Hassanali⁴, Ruchi Upmanyu⁵ and Alan J. Kivitz⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Advanced Arthritis Care & Research, Scottsdale, AZ, ³Genentech Inc, South San Francisco, CA, ⁴Genentech Inc, San Francisco, CA, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
Abstract Number: 2074 • 2012 ACR/ARHP Annual Meeting
Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Tomomi Date¹, Yukihiko Aikawa¹, Tetsuya Yamamoto¹, Hirokazu Narita¹, Shuichi Hirono² and Shunichi Shiozawa³, ¹Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, ²Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, ³Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Activator protein-1 (AP-1) is an important transcription factor for cytokine production and joint destruction in rheumatoid arthritis (RA), and a potential target for the…
Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Marie Kostine¹, Thomas Barnetche², Elodie Ardouin³, Marlene Joly⁴, Emilie Rabois⁵, Baptiste Glace Sr.⁶, Delphine Nigon⁷, Thierry Schaeverbeke⁸ and Christophe Richez⁹, ¹Rheumatology, CHU Pellegrin, Bordeaux, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Limoges University Hospital, Limoges, France, ⁴Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Purpan, Toulouse, France, ⁸Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁹Hôpital Pellegrin and Université Victor Segalen Bordeaux, France
Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…
Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Thierry Schaeverbeke¹, Philippe Gaudin², Aleth Perdriger³, Christian Roux⁴, Muriel Vray⁵, Stephanie Rouanet⁶, Ghislaine Steinberg⁷ and Fabien Etchepare⁸, ¹Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ²Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Rheumatology, Paris Descartes University, Paris, France, ⁵Institut Pasteur, Paris, France, ⁶Medical Department, Roche, Boulogne, France, ⁷Medical department, Roche, Boulogne, France, ⁸G.H. Pitié-Salpêtrière, Paris, France
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…
Abstract Number: 326 • 2012 ACR/ARHP Annual Meeting
Silencing Intraarticular Snail Expression Ameliorates Rat Collagen-Induced Arthritis Through Induction of Mesenchymal-Epithelial Transition in Synovial Fibroblasts
Chrong-Reen Wang¹, Shih-Yao Chen², Ai-Li Shiau³, Yuan-Tsung Li⁴, Ming-Fei Liu⁵ and Chao-Liang Wu², ¹Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁵Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Morphological characteristics of rheumatoid arthritis (RA) synovial fibroblasts (SF) are similar to transformed cells. We hypothesized that epithelial-mesenchymal transition (EMT) of SF regulated by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].